Dr. Ansell on FDA Approval of Subcutaneous Rituximab in Select Blood Cancers

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.

Related Content:

Mayo ClinicOncLive TVHematologic OncologyNon-Hodgkin LymphomaChronic Lymphocytic Leukemia
Dr Wirth on the LIBRETTO-001 Trial of Selpercatinib in RET Fusion+ Thyroid Cancer
Dr Phillips on the Evolution of BTK Inhibitors in MCL
First-Line Orelabrutinib Plus FCG Generates Rapid Molecule Remissions in CLL